Pall Corporation and Single Use Support Partner to Safeguard Storage and Transport Critical Biopharmaceuticals

December 16, 2020

Pall Corporation, a global leader in filtration, separation, and purification, announced a strategic partnership with Single Use Support GmbH, a leading provider of an innovative, end-to-end solution for safe handling of biologics from bulk manufacturing to fill-finish.

Pall Corporation will provide significant investment and partner with Single Use Support to distribute the RoSS platform which enhances Pall’s integrated solutions and will make the RoSS platform more accessible to Biopharma customers around the globe.

“Safe and reliable management of drug substances is a challenge for many Pall customers. Through our partnership with Single Use Support, Pall will be able to offer the Biopharma industry a fully validated end-to-end solution, which will enable our customers to bring life-saving drugs to the patient in a more efficient way,” explained Ed Hoare, Vice President and General Manager, Pall Corporation.

Single-Use Support’s RoSS platform consists of an innovative workflow solution, combining robust RoSS shells to protect single-use biocontainers, such as Pall’s Allegro™ biocontainer bags, throughout the process with systems allowing automated filling, controlled freezing/thawing and safe transportation.

“Through high-value liquid management systems, we help our customers safeguard a step that, while inefficient, is mission-critical in bioprocessing,” said Johannes Kirchmair, co-founder and Managing Director of Single Use Support.

Thomas Wurm, co-founder and Managing Director of Single Use Support further explained, “Pall is a global science and technology innovator and shares our mission to help customers solve complex challenges to improve quality of life around the world. Pall Corporation holds an unparalleled leadership position in bioprocessing technologies. Through our partnership, our innovative solution will become more accessible to customers worldwide.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”